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Background: Identification of new drugs against paediatric sarcomas represents an urgent clinical need that mainly
relies on public investments due to the rarity of these diseases. In this paper we evaluated the in vitro and in vivo
efficacy of a new maltol derived molecule (maltonis), belonging to the family of molecules named hydroxypyrones.
Methods: Maltonis was screened for its ability to induce structural alteration of DNA molecules in comparison to
another maltolic molecule (malten). In vitro antitumour efficacy was tested using a panel of sarcoma cell lines,
representative of Ewing sarcoma, osteosarcoma and rhabdomyosarcoma, the three most common paediatric
sarcomas, and in normal human mesenchymal primary cell cultures. In vivo efficacy was tested against TC-71 Ewing
sarcoma xenografts.
Results: Maltonis, a soluble maltol-derived synthetic molecule, was able to alter the DNA structure, inhibit proliferation
and induce apoptotic cell death in paediatric sarcoma cells, either sensitive or resistant to some conventional
chemotherapeutic drugs, such as doxorubicin and cisplatin. In addition, maltonis was able to induce: i) p21, p15 and
Gadd45a mRNA upregulation; ii) Bcl-2, survivin, CDK6 and CDK8 down-regulation; iii) formation of γ-H2AX nuclear
foci; iv) cleavage of PARP and Caspase 3. Two independent in vivo experiments demonstrated the tolerability and
efficacy of maltonis in the inhibition of tumour growth. Finally maltonis was not extruded by ABCB1, one of the major
determinants of chemotherapy failure, nor appeared to be a substrate of the glutathione-related detoxification system.
Conclusions: Considering that treatment of poorly responsive patients still suffers for the paucity of agents able to
revert chemoresistance, maltonis may be considered for the future development of new therapeutic approaches for
refractory metastatic patients.
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Sarcomas are uncommon and heterogeneous malignant
tumours that arise from mesenchymal tissues, such as bone,
cartilage or muscle. They account for around 1% of all hu-
man malignancies, thus being defined as rare diseases. To-
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reproduction in any medium, provided the orfrequent solid tumours in children and adolescents and have
therefore high social impact [1]. Paediatric sarcomas in-
clude either tumours carrying fusion oncoproteins, gene-
rated by recurrent chromosomal translocations (i.e. Ewing
sarcoma and alveolar rhabdomyosarcoma), or tumours lack-
ing defined genetic alterations and characterized by com-
plex karyotypes and genetic instability (i.e. osteosarcoma)
[2]. Despite this genetic diversity, they share an aggressive
natural history with rapid growth and marked tendency to
form metastases. In the pre-chemotherapeutic era, when
patients received surgery alone, survival rate was under
20% due to development of metastasis [3,4]. Since then,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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coma and Ewing sarcoma has improved dramatically
thanks to intensification of treatment schedule, better
supportive care and local therapy or use of risk stratifica-
tion for rhabdomyosarcoma, [5-8]. However chemotherapy
dose escalation implies higher rate of severe toxicity
(infertility, cardiomiopathy) and increased risk of life-
threatening late events, such as secondary malignancies
[9,10]. With a larger population of long-survivors, scien-
tific and patients’ associations are very sensitive to the
need of therapy improvement in terms of reducing side
effects and increasing quality of life, as well as potentiat-
ing efficacy of treatment in patients with metastatic dis-
ease. In this paper we explored the preclinical efficacy
of two new-generation maltol-derived synthetic mole-
cules named malten [N,N’-bis[(3-hydroxy-4-pyron-2-yl)
methyl]-N, N’-dimethylethylendiamine] and maltonis [4
(N),10 (N)–bis[(3-hydroxy-4-pyron-2-yl)methyl]-1, 7-di-
methyl-1, 4, 7, 10 tetraazacyclododecane] [11,12]. Both
chemical agents belong to the class of highly versatile
molecules hydroxypyrones, that include compounds bear-
ing anti-proliferative activities against a wide range of can-
cer cells, either alone or in combination with metals [13].
Particularly 3-hydroxy-2-methyl-4-pyrone (maltol) is a
natural compound used in food, beverage, tobacco brew-
ing and cosmetics for its flavour and antioxidant proper-
ties [14]. Maltol and its derivates were found to exhibit
anti-neoplastic activity attributed to the formation of re-
active oxygen species (ROS) as well as coordination prop-
erties towards metal ions [15-18]. For this reason, ligands
containing maltol have been developed and exploited as
new potential metal-based anti-tumor drugs [19]. Re-
cently, the anti-cancer potential of malten, a molecule
belonging to this class of poly-alkylamino-bis-maltolic
compounds has been confirmed in different tumor histo-
types [11,12]. Particularly the effect of malten was studied
in eight different cellular neoplastic models derived from
both hematopoietic and solid tumours such as cervix car-
cinoma, glioblastoma, pleural mesothelioma and alveolar
rhabdomyosarcoma: the latter resulted to be the more
sensitive histotype with an IC50 two or three folds lower
than the other models [11]. Since few treatment options
are amenable to sarcoma patients, we evaluated the effi-
cacy of both malten and maltonis in a representative panel
of patient-derived human rhabdomyosarcoma, osteosar-
coma and Ewing sarcoma cell lines. In vitro and in vivo ef-
fects on tumor growth were examined.
Methods
Chemicals and synthesis of maltolic compounds
All chemicals and compounds were purchased from
Sigma-Aldrich (St. Louis, MO, USA) at the highest qual-
ity commercially available. Malten and maltonis were
synthesized as previously described [12]. The purity ofmaltonis, over 99%, was checked by elemental analysis,
1H and 13C NMR and mass spectra.
DNA electrophoretic mobility assay and PCR inhibition
assay
An amount of 500 ng of pLL3.7 plasmid DNA was incu-
bated in 20 μl of 10 mM Tris-HCl (pH 7.4) in absence
or presence of the reported concentrations of maltonis,
malten and cisplatin (CDDP), for 2 hours at 37°C. After
incubation, DNA was separated by 0.8% agarose gel elec-
trophoresis (AGE) and then stained by ethidium bromide.
An aliquot of the same mixture was diluted to 0.25 pg/μl
and amplified (2 μl per assay) by real-time quantitative
PCR (Q-PCR) as previously described [11] using the
following sets of primers, designed with Primer Express
software [20]:
pLLF1 (F1): 5′-AATACCGCGCCACATAGCAG–3′,
pLLF1a (F2): 5′-ATTCTGAGAATAGTGTATGCGG
CG-3′,
pLLF1b (F3): 5′-CTCTTACTGTCATGCCATCCGTA
AG-3′,
pLLF2 (F4): 5′-GTTGTCAGAAGTAAGTTGGCCGC–3′,
pLLF2a (F5): 5′-TTGCCGGGAAGCTAGAGTAAGT
AG-3′,
pLLF3 (F6): 5′–GCTGCAATGATACCGCGAGAC–3′,
pLLR (R): 5′-GTGCACGAGTGGGTTACATCG–3′.
The reactions are characterized by a common reverse
primer and are able to amplify the same plasmid region
producing amplicons of different length (121, 179, 240,
301, 494 and 622 bp).
Cell cultures and pharmacological treatment
A panel of cell lines representative of rhabdomyosar-
coma, osteosarcoma and Ewing sarcoma were consid-
ered to evaluate malten and maltonis efficacy. Bone
marrow or dental pulp derived normal human mesen-
chymal stem cells (h-MSC) were obtained from healthy
donors or patients with benign bone lesions. After
washings, cells were plated in α-MEM (Lonza, Verviers,
Belgium), supplemented with 100 units/ml penicillin,
100 μg/ml streptomycin (Sigma-Aldrich, Saint Louis, MO)
and 20% inactivated fetal bovine serum (FBS) (Lonza).
Saos-2, U-2OS, SK-N-MC, and RD-ES were from the
American Type Culture Collection, ATCC; the alveolar
rhabdomyosarcoma cell lines SJ-RH30 and SJ-RH4 were
provided by Dr. A. Rosolen (University of Padua, Padua,
Italy) and Dr. D.N. Shapiro (St. Jude Children’s Hospital,
Memphis, TN) [21]; Ewing sarcoma cell lines TC-71 and
6647 were kindly provided by T.J. Triche (Children’s
Hospital, Los Angeles, CA); all other osteosarcoma
(IOR/OS9 and IOR/OS10) and Ewing cell lines (LAP-
35) were obtained from the Rizzoli laboratories and
were previously described [22,23]. The RD/18 cell
line is a clone of the commercially available human
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boratories), obtained at the Cancer Research Section,
University of Bologna, Bologna, Italy [24]. Resistant vari-
ants of U-2OS and Saos-2 osteosarcoma cell lines were
obtained by subsequent exposure to increasing concentra-
tions of doxorubicin or cisplatin as previously described
[25,26]. The most relevant mechanism of drug resistance
in U-2OS/DX580 and Saos-2/DX580 is the increased DX ef-
flux mediated by ABCB1 (MDR1) membrane transporter
as consequence of both amplification and over-expression
of MDR1 [25,27]. The major mechanism of CDDP resist-
ance is the increase of both intracellular levels and enzym-
atic activity of glutathione-S-transferase P1-1 (GSTP1-1)
and of, at a much lower extent, μ-class GST [26]. TC/
DOXO8 was generated by transfection with an expression
vector containing full-length MDR1 cDNA and selected
in doxorubicin, thus achieving ABCB1-mediated in-
creased DX efflux [28]. All cell lines have been tested
for absence of mycoplasma contamination with MycoA-
lert (Lonza) -last control March 2013- and authenticated
by STR analysis using genRESVR MPX-2 and genRESVR
MPX-3 kits (serac, Bad Homburg, Germany). The follow-
ing locus were verified: D16S539, D18S51, D19S433,
D21S11, D2S1338, D3S1358, D5S818, D8S1179, FGA,
SE33, TH01, TPOX VWA. Last control was performed in
November 2012. Cells were cultured in a humidified at-
mosphere at 37°C in Iscove Modified Dulbecco’s medium,
IMDM (Lonza) supplemented with 10% FBS, (Lonza) 1%
penicillin-streptomycin. Malten and maltonis were dis-
solved in double-distilled water at the final concentra-
tion of 10 mM (stock solution), stored in aliquots
at -80°C and diluted before use. Cells were exposed to
malten or maltonis at the reported concentrations with
subsequent administration every 24 hours. The GSTP1
inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexane
(NBDHEX), kindly provided by Professor Anna Maria
Caccuri, University of Rome “Tor Vergata”, Italy, was
used in combination with maltonis (0.3-100 μM) or
CDDP (1 μg-100 μg/ml) for 72 h at 0.3-0.75 μM [29].
Cell growth inhibition, soft agar colony formation,
apoptosis and cell cycle analysis
To assess cellular proliferation, MTT assay (Roche,
Indianapolis, IN) was employed according to manufac-
turer’s instructions. Cells were plated into 96 well-plates
(range 2,500-10,000 cells/well) in IMDM plus 10% FBS,
or α-MEM plus 20% FBS. After 24 hours, various con-
centrations of malten and maltonis (0.3-30 μM), were
added and cells were exposed up to 72 hours. Analysis
of cell cycle was performed after 48 hours of treatment
(FACSCalibur, Becton Dickinson, Italy) whereas apop-
tosis was assayed after 72 h with Mebcyto Apoptosis Kit
(MBL International, Woburn, MA) according to the
manufacturer instructions. Anchorage-independent growthwas evaluated after seeding of 3,300-75,000 cells/dish in
IMDM-10% FBS plus 0.33% agarose (SeaPlaque, FMC Bio-
Products, Rockland, ME) with a 0.5% agarose/IMDM-10%
FBS underlay [30].
RNA extraction and real time RT-PCR
Total RNA was extracted from TC-71 cells control and
treated with maltonis (1-3 μM) after 72 hours of incuba-
tion using RNeasy Mini Kit (Qiagen) or TRIzol (Invitro-
gen). RNA was employed for Q-PCR evaluation assay
(37 different genes simultaneously amplified in 100-well
discs, Qiagen, Hilden, Germany) and analysis of data
were performed as previously described, refer to Additional
file 1 for the complete primers sets sequences [11]. Q-PCR
of Gadd45α was performed with the following primers:
Fw-Gadd45α: 5′-GACCCCGATAACGTGGTGTT-3′, Rv-
Gadd45α: 5′-CCTGGATCAGGGTGAAGT -3′. GAPDH
endogenous control was performed with Taqman assay #
Hs99999905_m1 (Applied Biosystems, Foster City, CA).
Samples were analyzed using an ABI Prism 7900 Detection
System (Applied Biosystems), according to manufacturer’s
instructions. Expression levels of target genes were nor-
malized to that of glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), and the relative quantification analysis
was performed on the basis of either 2-ΔΔCT and com-
parative quantitation methods.
DNA laddering evaluation
The DNA laddering assay was performed as previously
reported [31].
Immunofluorescence and evaluation of nuclear
fragmentation
After 24 hours of treatment with the reported concentra-
tions of maltonis, cells were stained with anti-phospho-
H2AX antibody (Cell Signaling, Danvers, MA,) and
counterstained with DAPI as previously described [32].
Confocal images were acquired with Leica TCS SP2,
magnification 63X (Wetzlar, Germany). For evaluation
of nuclear fragmentation, cells were seeded in 60-mm
petri dishes and 24 hours later treated with 1-3 μM of
maltonis. 72 h after treatment, cells were fixed in
methanol/acetic acid (3:1) for 15 min and stained with
50 ng/ml Hoechst 33258 (Sigma). Cells with three or
more chromatin fragments were considered apoptotic.
The percentage of nuclei showing fragments was calcu-
lated considering 1,000 nuclei.
Immunohistochemistry
Sections (5 μm) from formalin-fixed, paraffin-embedded
tumours xenografts were placed on poly-l-lysine–coated
slides (Sigma). Avidin-biotin-peroxidase procedure was
used for immunostaining, as previously described [33].
For morphological evaluation of nuclear alterations,
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and eosin (Sigma). Detection of Ki-67 was performed on
sections pre-treated with a citrate buffer solution
[0.01 mol/L citric acid and 0.01 mol/L sodium citrate
(pH 6.0)] in a microwave oven at 750 W and stained with
the MIB-1 primary antibody (1:100 dilution; Calbiochem-
Novabiochem, San Diego, CA). TUNEL assay was per-
formed with ApopTag® Plus Peroxidase in situ apoptosis
kit (Merck Millipore, Billerica, MA) according to manu-
facturer’s instructions.Western blotting
Cells were lysed with phospho-protein extraction buf-
fer (Merck Millipore) supplemented with protease-
phosphatase cocktail inhibitor (Sigma). 40 μg total
lysates were then resolved on a 10% or 15% Tris-HCl
gel and immunoblotted with the following specific anti-
bodies: anti-BAX (6A7) monoclonal antibody (Santa Cruz
Biotechnology, Dallas TX), anti-p21 (H-164) polyclonal
antibody (Santa Cruz Biotechnology), anti-PARP poly-
clonal antibody (Cell Signaling Technologies), anti-BCL2
(clone100) monoclonal antibody (Merck Millipore), anti-
caspase 3 (8G10) monoclonal antibody (Cell Signaling
Technologies), anti-GAPDH polyclonal antibody (Santa
Cruz Biotechnology).In vivo evaluation of maltonis efficacy
To evaluate anti-tumour efficacy, athymic Crl:CD1-Foxn1
nu (referred to as nude) mice were purchased from
Charles River, Italy. Five weeks old mice were injected
subcutaneously (s.c.) with 7.5 × 106 TC-71 cells/mouse to
obtain tumours xenografts. When tumours started to be
measurable (approximately 7 days after cell inoculation)
mice were randomized in two groups: i) control (n = 9) and
treated (n = 5) ii) control (n = 5) and treated (n = 4).
Control group was treated with vehicle alone (PBS),
treated group received maltonis daily intra-tumour for
two subsequent cycles of 5 days. Treated mice were
injected with: i) 20 mg/Kg maltonis in the first cycle
and 40 mg/kg in the second one or ii) 40 mg/kg for
both cycles. Tumour dimensions were measured twice
weekly and tumour volume was calculated as π[√(a · b)]
3/6 where “a” is the maximal tumour diameter and “b”
is the tumour diameter perpendicular to “a”. Four days
after the end of treatment mice were sacrificed and
tumour samples were collected.
All animal experiments were performed according to
Italian law 116/92 and European directive 2010/63/UE. Ex-
perimental protocols were reviewed and approved by the
Institutional Animal Care and Use Committee (“Comitato
Etico Scientifico per la Sperimentazione Animale”) of the
University of Bologna, and forwarded to the Italian Minis-
try of Health.Serum glucose, urea, and transaminase levels
Control or maltonis-treated mice were analyzed to verify
whether the maltol derived compound modulated serum
levels of glucose or induced suffering at hepatic or sys-
temic level. Before the sacrifice, mice were sampled for
blood. Determination of serum concentration of glucose
and other enzymes was done.
Statistical analysis
Differences among means were analyzed using a two-
sided Student’s T test. When data were not normally
distributed, the nonparametric Mann-Whitney rank-sum
test was used. Correlations between two variables were
obtained by Pearson test; differences among percentages
with Chi Square test. IC50 values were calculated with
CalcuSyn software (Biosoft, Ferguson, MO).
Results
Maltonis synthesis, screening and biological effect on tumour
cell lines and normal human mesenchymal stem cells
Maltonis, a derivative of malten, (poly-alkylamino-bis-mal-
tolic molecule) was obtained as a white solid perchlorate
salt (L.3HClO4
. H2O), stable at light, air and room tempera-
ture, and soluble in water (Additional file 2-see Materials
and Methods) [11,12]. To evaluate its ability to interfere
with the structure of nucleic acids, plasmid DNA was ex-
posed to malten and maltonis and separated by agarose gel-
electrophoresis: DNA treated with both compounds failed
to migrate in agarose gel (Figure 1A, left panel). Moreover,
we applied the recently developed PCR inhibition assay that
detects covalent DNA modifications (Figure 1B) [11]. Cis-
platin was used as control of known therapeutic molecule
able to induce both single and double strand crosslinking
[11]. Doubling the amplicon length, an exponential loss of
PCR efficiency was observed in maltonis and malten treated
DNA, while cisplatin (CDDP) treatment induced, as ex-
pected, a linear decrease of DNA amplificability (Figure 1B,
Additional file 3) as consequence of the induced DNA
modification (Figure 1A). The efficiency of delay appeared
to be higher in maltonis- than in malten-treated samples.
We next evaluated the efficacy of the two compounds
against sarcoma cell growth. Two rhabdomyosarcoma, two
osteosarcoma and two Ewing sarcoma cell lines displayed
marked reduction of cell growth after 72 hours of treatment
with maltonis (IC50 values ranging from approximately
3 μM to 18 μM) (Figure 1C); conversely malten showed
modest efficacy only in the two Ewing cell lines (IC50
values between 25 μM and 40 μM). Similar results were ob-
tained in anchorage independent conditions. Particularly
after treatment with maltonis we observed a reduction of
both the number and the size of colonies (Figure 1D,
Additional file 4); whereas malten induced no significant
impairment of growth. These data confirmed the therapeutic
potential of maltonis but not malten in the management of
Figure 1 (See legend on next page.)
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Figure 1 Malten and maltonis effect on DNA structure and sarcoma cell growth. (A) Effects of the two compounds on electrophoretic
migration of plasmid DNA. After 2 hours incubation in presence of 4 mM malten, 4 mM maltonis or 25 μM CDDP, circular plasmid DNA (pLL3.7)
was separated by agarose gel electrophoresis. Supercoiled (white arrow), open circular (black arrow) plasmid form and high molecular weight
DNA complexes formation (black bar) are indicated. (B) PCR inhibition assay. Amplification delay (folds) was calculated for each set of primers
(for details see Additional file 3) as the difference between the Ct values of treated and untreated samples. Graphical representation of the
exponential decrease of the number of amplifiable DNA sequences after incubation with malten, maltonis or CDDP. (C) Histogram showing IC50
values for malten (light bars) and maltonis (dark bars) in a panel of sarcoma cell lines. RMS, rhabdomyosarcoma; OS, osteosarcoma; ES, Ewing
sarcoma. Values are expressed as mean of three independent experiments ± SE. (D) Maltol derived compounds inhibit tumour growth in
anchorage-independent conditions: columns are the mean of three independent experiments ± SE performed on RD/18 (seeded cells: 10,000/dish),
U-2OS(seeded cells: 10,000/dish) and TC-71 (seeded cells: 3,300/dish) cells. Statistical analysis was performed by Student’s t test: *P < 0.05; **P < 0.01.
(E) Fold increase in drug resistance to conventional drugs (light grey) or to maltonis (black): fold resistance is calculated on the values of IC50 of
each resistant cell line against its respective sensitive parental one. Values are representative of three independent experiments.
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a larger panel of cell lines and to three human normal mes-
enchymal stem cells, considered the cell of origin of sarco-
mas (Table 1) [34-36]. Sensitivity varied in a range from 2.6
to 12.5 μM in patient-derived cell lines, without any remark-
able difference either among the tumour histotypes nor in
sarcomas carrying specific translocations or displaying
complex genetic aberrations. Interestingly, IC50 values of
maltonis in the different cell lines correlated to cell doub-
ling times (r = 0.59, p = 0.01, Pearson correlation test),
whereas human normal mesenchymal stem cells appeared
to be unaffected by the compound. Moreover, maltonis wasTable 1 Maltonis mean IC50 values in a panel of human deriv
Histotypea Cell lineb IC50 μM (± SE)c,f
RHABDOMYOSARCOMA RD/18 6.8 (± 2.1)
SJ-RH4 5.6 (± 1.3)
SJ-RH30 9.9 (± 2.7)
OSTEOSARCOMA IOR/OS10 5.5 (± 1.3)
IOR/OS9 8.6 (± 1.8)
Saos-2 11.9 (± 3.1)
Saos-2/DX580 39.3 (± 2.6)
Saos-2/CDDP6ug 43.3 (± 6.8)
U-2OS 12.5 (± 0.7)
U-2OS/DX580 16.5 (± 0.4)
U-2OS/CDDP4ug 56.1 (± 1.4)
EWING SARCOMA 6647 3.1 (± 1.4)
LAP-35 11.6 (± 0.7)
SK-N-MC 3.9 (± 0.5)
TC-71 2.6 (± 1.4)
TC/DOXO8 5.0 (± 0.1)
h-MSC MES1 >50
MES2 >50
DP-15 >50
aHistotype: origin of the patient-derived cell line.
bcell line name.
cmean IC50 calculated over three idependent experiments ± SE.
dgenetic alterations associated to the cell line.
edoubling time of the indicated cell line.
fIC50 values statistically correlate with cell doubling times (r = 0.59, p = 0.01, Pearson
n.d. not determined.dramatically active either in cells resistant to multiple drugs
(e.g. doxorubicin, epirubicin, vincristine) or resistant to cis-
platin [25,26,28] (Figure 1E, Table 1). In particular, cells
transfected with (TC/DOXO8) or overexpressing ABCB1/
MDR1 gene (U-2OS/DX580, Saos-2/DX580) were sensitive
to maltonis, indicating that the drug was not extruded by
ABCB1 transporter. Cells resistant to cisplatin maintained
very low levels of resistance to maltonis (around 4-fold)
compared to parental cell lines, indicating that a partial
cross-talk in the mechanisms of action between the two
drugs may exist (Figure 1E). Since activity of glutathione S-
tranferase P1 (GSTP1) was demonstrated to be relevant fored sarcoma and human normal mesenchymal cells
Genetic alterationd Doubling time (hours)e,f
Altered 11p15.5 chromosome 22 ± 0.1
(2;13)(q35;q14) PAX3 FKHR 25 ± 1.2
(2;13)(q35;q14) PAX3 FKHR 26 ± 1.0
Complex Karyotype 30.4 ± 2.6
Complex Karyotype 44.5 ± 2.4
Complex Karyotype 36.1 ± 4.4
Complex Karyotype 75.6 ± 5.7
Complex Karyotype 44.3 ± 4.1
Complex Karyotype 18.3 ± 0.2
Complex Karyotype 45.3 ± 4.7
Complex Karyotype 38.6 ± 4.1
t(11;22)(q24;q12) EWSR1-FLI1 TYPE II 29 ± 2.3
t(11;22)(q24;q12) EWSR1-FLI1 TYPE II 48.6 ± 4.2
t(11;22)(q24;q12) EWSR1-FLI1 TYPE I 26.9 ± 0.5
t(11;22)(q24;q12) EWSR1-FLI1 TYPE I 14.9 ± 1.4
t(11;22)(q24;q12) EWSR1-FLI1 TYPE I 22.6 ± 2.8
n.d. n.d.
n.d. n.d.
n.d. n.d.
correlation test).
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cells, we tested the efficacy of maltonis in presence of the
GSTP1 inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)
hexane (NBDHEX) [26,29]. NBDHEX did not modulate the
efficacy of maltonis but reduced the IC50 values of cisplatin
as expected (Additional file 5), thus indicating that the
glutathione-related detoxification system did not limit mal-
tonis cytotoxic effect.
Maltonis induces modulation of the gene expression profile
To better define the molecular response triggered by
maltonis, we evaluated the expression of genes knownFigure 2 Molecular response of TC-71 cells to maltonis exposure. (A)
exposed to maltonis for 48 hours at the concentration of 3 μM. Gene trans
expression and evaluated as fold induction compared to untreated cells. Re
three independent experiments. (B) Histogram shows relative PCR quantific
GAPDH expression was used as internal control; TC-71 untreated sample w
total cell lysates from control or maltonis treated TC-71 cells. Equal loadingto regulate cell cycle progression, proliferation and
apoptotic response by Q-PCR [11]. Exposure of TC-71
Ewing sarcoma cells to maltonis, at the dose of 3 μM for
48 hours, modified the transcript levels of some genes
involved in the control of cell cycle progression: we moni-
tored up-regulation of the cyclin-dependent kinase inhibi-
tors (CDKI) CDKN2B (p15) and CDKN1A (p21), and
down-regulation of cyclin-dependent kinase 6 (CDK6)
and cyclin-dependent kinase 8 (CDK8) mRNA levels
(Figure 2A). In addition, maltonis treated cells were
characterized by a marked increase of Gadd45a mRNA
levels and a strong down-regulation of survivin (BIRC5)Gene expression modifications induced by maltonis. Cells were
cripts abundance was assessed by Q-PCR, normalized with GAPDH
lative expression (folds) is reported as mean (± SD) resulting from
ation of Gadd45-α mRNA (± SD) after 3 or 10 μM maltonis treatment.
as used as calibrator. (C) Western blot evaluation of BCL-2, and p21 on
was monitored with anti-GAPDH blotting (lower line).
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not regulated after treatment with malten [11]. The induc-
tion of Gadd45a mRNA was also confirmed by Q-PCR
(Figure 2B). Two independent western blotting analysis
confirmed that levels of protein expression were modu-
lated consistently with gene profiling results: p21 were
increased in TC-71 treated with maltonis, whereas the
anti-apoptotic factor BCL-2 was diminished (Figure 2C).
Maltonis induces perturbation of cell cycle progression in
sarcoma cells
The analysis of possible effects on cell cycle progression
revealed the ability of maltonis to alter the cellular
distribution in all the considered cell lines. Particularly
we observed an accumulation of the rhabdomyosarcoma
RD/18 cells in G2-M (Figure 3A) and of the osteosar-
coma and Ewing sarcoma cells in G1 phase (Figure 3A);
thus pointing out to the ability of this molecule to inter-
fere with cell cycle progression as also confirmed by the
modulation of CDKIs and CDKs (Figure 2A-C).
Maltonis induces DNA damage and promotes apoptosis
of sarcoma cells
Since the gene expression profiling and western blotting
validations (Figure 2) suggested that an impairment of
the pro/anti-apoptotic balance might be triggered by
maltonis, we investigated RD/18, U-2OS and TC-71 cell
death after exposure to the maltol derived compound.
Flow cytometry analysis of AnnV-PI stained control and
treated cells at 72 hours revealed that death occurred in
all the three histotypes with different degrees (Figure 3B):
TC-71 and RD/18 appeared to be the more sensitive to
maltonis induced cell death, whereas U2-OS were only
partly affected.
We also assessed the phosphorylation of histone H2AX
(γ-H2AX) as marker of DNA-damage response. TC-71Figure 3 Maltonis effect on cell cycle and apoptosis. (A) Cell cycle eva
with maltonis 3 or 10 μM. Data are expressed as mean percentages of two
phase are significantly different after treatment compared to the respective
analysis, expressed as percentage of live (black), apoptotic (dark grey) or ne
with 3 or 10 μM maltonis. Values are representative of 3 independent expe
different after treatment compared to the respective controls (P≤ 0.02 by Ccells showed a precocious (treatments of 24 hours) in-
crease of γ-H2AX levels when treated with maltonis at the
concentration of 3 μM (Figure 4A, Additional file 6). In
addition, the induction of apoptosis was confirmed mor-
phologically by monitoring nuclear fragmentation after
Hoechst staining (Figure 4B) and molecularly, at higher
doses, by evaluating inter-nucleosomal cleavage and
subsequent DNA laddering (Figure 4C). In TC-71 cells
we were able to demonstrate PARP and Caspase 3 cleav-
age by western blotting after exposure to 3 μM maltonis
(Figure 4D). Moreover, maltonis treatment was able to
induce accumulation of BAX protein (Figure 4D).
In vivo evaluation of maltonis efficacy against Ewing
sarcoma xenografts
The anti-tumour activity of maltonis was evaluated in
TC-71 xenograft model. TC-71 Ewing sarcoma cell line
displays a very rapid cell growth in vivo and can therefore
be representative of very aggressive sarcomas. In the first
pilot experiment, we evaluated the therapeutic potential
and toxicity of maltonis. Seven days after cell injection,
when tumours began to be measurable, mice were divided
into two subgroups: control mice were treated with ve-
hicle alone (phosphate buffered saline), whereas treated
mice received injection of maltonis, at increasing drug
concentrations (20 mg/Kg in the first cycle and 40 mg/kg
in the second one); four days after the end of the second
cycle mice were sacrificed. Intra-tumour drug administra-
tion was chosen as first attempt in order to achieve higher
local concentration and test only direct activity of the drug
but not of its metabolites. At the indicated doses maltonis
was very well tolerated: we did not observe any significant
changes in mice weight, blood glucose and urea levels or
hepatic enzymes activity (Additional file 7) or other sign
of collateral toxicity. As reported in Figure 5A decrease in
the growth rate was observed in maltonis-treated groupluation of RD/18, U-2OS and TC-71 cells after 48 hours of treatment
independent experiments. Percentage of cells in the G1 or G2/M
controls (P < 0.01E-16 by Chi Square test for 10 μM). (B) Annexin V-PI
crotic (light grey) cells, in a panel of sarcoma after 72 hours treatment
riments. Percentage of apoptotic or necrotic cells are significantly
hi Square).
Figure 4 Maltonis induces DNA damage and triggers apoptosis in sarcoma cell lines. (A) Induction of H2AX phosphorylation (γ-H2AX) in
TC-71 cells after exposure for 24 hours to 3 μM maltonis (magnification × 40) (B) Evaluation of nuclear fragmentation after staining with
HOECHST-33258 on untreated or 3, 10 μM treated RD/18, U-2OS or TC-71 cells after 72 h. Histogram shows mean percentages ± SE of fragmented
nuclei out of 1000 considered in three independent experiments. Statistical analysis was performed by Student’s t test: *P < 0.05. Representative
pictures are also shown (magnification × 400). (C) Apoptosis-related DNA fragmentation induced by maltonis exposure after 72 hours at 10 or
25 μM in TC-71 cells. (D) Western blotting on TC-71 total cell lysates from control or maltonis treated cells (3 μM for 72 h) showing caspase 3 and
PARP cleavage as well as BAX induction. Equal loading was monitored with anti-GAPDH or beta-actin blotting (lower lines).
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ney test). Haematoxylin–eosin staining (HE) and TUNEL
assay showed presence of apoptotic nuclei, featuring nu-
clear condensation and apoptotic body formation intreated samples (Figure 5B and C), sustaining the pro-
apoptotic effects of maltonis. Evaluation of Ki67 from
histological tissues of control and treated samples demon-
strated that maltonis was also very effective in blocking
Figure 5 Maltonis inhibits tumour growth and induces apoptotic cell death in xenograft model of sarcoma. (A) Inhibition of TC-71 tumour
growth in nude mice. Mice were treated for two cycles of 5 days with maltonis (1st cycle: 20 mg/kg or 2nd cycle: 40 mg/kg) or with vehicle (PBS). Panel
shows mean tumour size ± SE of control or treated mice. (B) Morphologic hematoxylin-eosin of fragmented nuclei on tumour-samples derived from
two controls (vehicle) or maltonis treated mice (magnification, ×400). (C) TUNEL assay evaluation of apoptotic nuclei after treatment with maltonis
(magnification × 200. (D) Representative immunohistochemical evaluation of Ki67 in controls and maltonis treated tumours (magnification ×200).
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http://www.biomedcentral.com/1471-2407/14/137tumour proliferation (Figure 5D) In the second experiment,
mice were treated with the highest dose of maltonis
(40 mg/kg for five consecutive days/week for two times).
Growth inhibition was confirmed (Figure 6).
Discussion
In this work we demonstrated that maltonis, a maltol
derived compound, significantly reduces sarcoma cell
viability and tumour growth either in monolayer and in
anchorage-independent conditions while being basically
ineffective on normal human mesenchymal stem cells.
We also showed that maltonis was more effective in tar-
geting sarcoma growth than its companion compound
malten. Although previous chemical analysis indicated
that malten should be more prone than maltonis to give
non covalent approaches with negatively charged DNA
[12], in vitro evaluation of impaired DNA properties
(migration and amplificability) showed that maltonis in-
duces a 9-fold higher amplification delay than malten,
thus underlying a stronger perturbation of DNA struc-
ture which might be responsible for the major efficacy in
sarcoma inhibition. Maltonis was found to inhibit cell
proliferation and induce cell death. Accumulation of cells
in G1 phase of cell cycle was observed in the U-2OS
osteosarcoma and TC-71 Ewing cell lines, whereas in
the rhabdomyosarcoma RD/18 model, accumulation
was mainly in G2-M phase. In TC-71 the accumulation
in G1 phase was coherent with the observed induction
of p15 mRNA and increased p21 protein levels. Besides
the cytostatic effect, maltonis was also able to deliver a
cell death signal in all the three histotypes as demon-
strated by flow cytometry analysis. Apoptosis was con-
firmed by nuclear fragmentation and detection of cleaved
caspase 3 and PARP in TC-71 cells after exposure to theFigure 6 Maltonis induces tumour inhibition in TC-71
xenografts. Mice were treated for two cycles of 5 days with 40 mg/Kg
of maltonis/week. Panel shows mean tumour size + SE of control or
treated mice.drug. The in vitro efficacy of this new compound was also
confirmed in vivo against TC-71 Ewing sarcoma xeno-
grafts. Drug treatment produced a decrease in the growth
rate of xenografts after treatment with maltonis in two
separated independent experiments. Tumour volume
reduction was likely due to both inhibition of cell prolifer-
ation and induction of apoptosis, thus substantially
confirming what observed in vitro. Considering that
maltonis activity has never been evaluated in vivo be-
fore, we could also provide evidence that the compound
is well tolerated in mice at the highest and effective dose
of 40 mg/kg.
Maltonis induces DNA fragmentation and recruits
γH2AX [37,38] and Gadd45α [39], thus suggesting in-
volvement of a DNA damage response. Similarly, the
well characterized chemotherapeutic drug cisplatin has
been recently reported to increase Gadd45α levels and
to induce γH2AX foci [40,41]. Although the effects of
maltonis and cisplatin could be interpreted as similar,
the analysis of cisplatin-resistant variants indicated quite
different mechanisms of action. Cells highly resistant to
cisplatin (63 and 112 fold increase in resistance com-
pared to sensitive parental cells) maintained a low level
of residual resistance to maltonis (around 4 fold), thus
suggesting that the two drugs most probably do not
share common mechanisms of action and, therefore, do
not undergo the same mechanisms of resistance [26].
Differently from cisplatin, that once inside the cell has
to be aquated before being able to interact with DNA
(and whose activity may thus be limited by interactions
with endogenous detoxification molecules), maltonis is
supposed to be able to enter the cell and to react directly
with DNA. Physical interaction with the drug, demon-
strated by cell free assays, is sufficient to alter nucleic
acid properties and recruit the DNA damage repair sys-
tem. This triggers characteristic biological effects, such
as perturbation of cell cycle that culminate in activation
of an irreversible cell death program. Considering that
maltonis is not extruded by ABCB1, one of the major
determinants of chemotherapeutic failure in osteosarcoma
[42], this drug appears to be particularly interesting for a
possible future treatment of sarcoma, offering an effective
option for tumour inhibition also in refractory or resistant
patients. A lesson learned from other neoplasms is that
biologically disparate entities need subtype-specific treat-
ments and therefore therapy should be designed in a
disease-specific fashion according to the underlying biol-
ogy. However rarity of sarcoma frequently couples with
rarity of the target, making development of new, targeted
drugs even less probable. Thus the identification of a new
drug with effects similar to conventional chemothera-
peutic agents, but exploiting different mechanisms of
action and therefore active whenever doxorubicin, vin-
cristine and cisplatin are ineffective, may overcome the
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orphan diseases.
Overall, although further investigations are required in
terms of dosage and schedule optimization, our findings
propose maltonis as a potential candidate for the manage-
ment of sarcomas. The designed synthetic procedure to
obtain maltonis is quite simple and it does not contain
hard multistep reactions. The products are obtained in
good yield and already in a gram scale from commercial
or well known starting molecules (maltol and 1,7-di-
methyl-1,4,7,10-tetraazacyclododecane or 1,4-dimethylety-
lendiamine). This let us foresee an easy and low-cost
synthetic scale up of the compound. Considering the al-
most complete absence of suitable option out of classical
chemotherapeutic agents in the last two decades, maltonis
might fulfill the need of new stable and easily synthesiz-
able compounds effective especially for those refractory
and metastatic sarcomas with poor outcome.Conclusions
This article demonstrates the efficacy of maltonis, a
maltol-derived compound, on sarcomas and particularly
on multidrug- and cisplatin-resistant cells, thus leading to
the possible development of a new drug to be exploited in
sarcoma patients both relapsed after first-line treatments
or with metastasis at the diagnosis.Additional files
Additional file 1: List and sequences of primers employed for QPCR
assay. Description of data: forward and reverse primers sets for all gene
analysed in the QPCR assay to evaluate transcriptional modulation in
maltonis treated cells.
Additional file 2: Synthetic pathway to obtain malten and maltonis.
Description of data: Maltol (1), appropriately protected (2) and activated
(3), was reacted with the polyamine (4) or (5) in THF in the presence of
triethylamine (TEA) as a base. The treatment with 10% perchloric acid
ethanol solution allows the simultaneous deprotection of the hydroxyl
function and the cleansing of compounds thus avoiding tedious and
expensive chromatographic purifications. Both compounds are obtained
as hydroperchlorate white solid salt.
Additional file 3: Amplification delay (folds) for each set of primers
as depicted in the “Primer Pair” column. Description of data:
Amplification delay (folds) was calculated for each set of primers as the
difference between the Ct values of treated and untreated samples.
Additional file 4: Effect of maltonis in anchorage independent-
condition in a panel of sarcoma cell lines. Description of data:
Representative images of anchorage independent growth of RMS, OS
and ES with or without malten (30 μM) and maltonis (10 μM).
Magnification × 40.
Additional file 5: Combined treatment with NBDHEX and CDDP or
maltonis in cisplatin resistant osteosarcoma cell lines. Description of
data: A dose of NBDHEX inhibiting GSTP1 activity but giving no growth
inhibition was combined with increasing doses of CDDP or maltonis.
Additional file 6: Induction of H2AX phosphorylation (γ-H2AX) in
TC-71 cells after 3 μM maltonis treatment. Description of data:
confocal microscopy images of control or 3 μM maltonis treated TC-71
cells after 24 h exposure. Magnification × 63.Additional file 7: Body mass and serum glucose, urea and
transaminase levels in control and treated mice. Description of data:
Before the sacrifice, mice were sampled for blood and determination of
serum concentration of glucose and other enzymes was done. Moreover
mean plus SE was calculated for mice weight in the two groups.
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